### SMALL MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2285</td>
<td>Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor</td>
</tr>
<tr>
<td>2286</td>
<td>Gramicidin A Induces Metabolic Dysfunction and Energy Depletion Leading to Cell Death in Renal Cell Carcinoma Cells</td>
</tr>
<tr>
<td>2296</td>
<td>Developing Lipid Nanoparticle-Based siRNA Therapeutics for Hepatocellular Carcinoma Using an Integrated Approach</td>
</tr>
<tr>
<td>2308</td>
<td>BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models</td>
</tr>
<tr>
<td>2319</td>
<td>PRIMA-1Met/PR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa</td>
</tr>
<tr>
<td>2320</td>
<td>Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo</td>
</tr>
<tr>
<td>2331</td>
<td>AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models</td>
</tr>
<tr>
<td>2342</td>
<td>UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo</td>
</tr>
<tr>
<td>2353</td>
<td>SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis</td>
</tr>
<tr>
<td>2364</td>
<td>Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model</td>
</tr>
<tr>
<td>2375</td>
<td>Isolation of a Novel Thioflavin S–Derived Compound That Inhibits BAG-1–Mediated Protein Interactions and Targets BRAF Inhibitor–Resistant Cell Lines</td>
</tr>
</tbody>
</table>
**The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants**

Michaela Medová, Benoît Pochon, Bruno Streit, Wieslawa Blank-Liss, Paola Francica, Deborah Stroka, Adrian Keogh, Daniel M. Aebersold, Andrée Blaukat, Friedhelm Bladt, and Yitzhak Zimmer

**Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer**

Huifang Li, Mohamed D.H. Hassona, Nathan A. Lack, Peter Averio-Cilies, Eric Leblanc, Peyman Tavassoli, Natalia Kanaan, Kate Frewin, Kriti Singh, Hans Adomat, Konrad J. Böhm, Helge Prinz, Emma Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov

**177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy**

Josefine Reber, Stephanie Haller, Christopher P. Leamon, and Cristina Müller

**MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma**

Anthony W. Gebhard, Priyesh Jain, Rajesh R. Nair, Michael F. Emmons, Rauf F. Argilagos, John M. Koomen, Mark L. McLaughlin, and Lori A. Hazlehurst

**A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity**


**Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX**

Bart Cornelissen, Andrew Waller, Sarah Able, and Katherine A. Vailis

---

**The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells**

Sandeep Sreevalsan and Stephen Safe

**In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome**

Liang Zhang, Lan V. Pham, Kate J. Newberry, Zhishuo Ou, Rong Liang, Jianfei Qian, Lu Hong Sun, Marzenna Blonska, Yun You, Jing Yang, Xin Lin, Alex Rollo, Archito T. Tamayo, John Lee, Richard J. Ford, Xiurong Zhao, Larry W. Kwak, Qing Yi, and Michael Wang

**Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide**

Hau-Lun Huang, Hui-Ping Hsu, Shu-Chu Shieh, Yang-Sheng Chang, Wei-Ching Chen, Chien-Yu Cho, Chiao-Fang Teng, Il-Jen Su, Wen-Chun Hung, and Ming-Derg Lai

**PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy**

Jeremy P.H. Chow, Wing Yu Man, Mao Mao, Han Chen, Florence Cheung, John Nicholls, Sai Wah Tsao, Maria Li Lung, and Randy Y.C. Poon

**Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylation Anticancer Drug Temozolomide**

Marcus Eich, Wynand Paul Roos, Teodora Nikolova, and Bernd Kaina

**Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib**

Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew D. Redfern, Lisa M. Stuart, Gregory J. Goodall, and Peter J. Leedman

**Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax**

Kan He, Xingnan Zheng, Lin Zhang, and Jian Yu
miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Gal Zhao, Bo Wang, Yang Liu, Jun-gang Zhang, Shi-chang Deng, Qi Qin, Kui Tian, Xiang Li, Shuai Zhu, Yi Niu, Qiong Gong, and Chun-you Wang

Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
Yan Long, Wen-Bin Tsai, Medhi Wangpaichitr, Takashi Tsukamoto, Niramol Savaraj, Lynn G. Feun, and Macus Tien Kuo

Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Hae-June Lee, Changhwan Yoon, Benjamin Schmidt, Do Joong Park, Alexia Y. Zhang, Hayriye V. Erkizan, Jeffrey A. Toretsky, David G. Kirsch, and Sam S. Yoon

TOOLS AND TECHNOLOGIES
Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non-Small Cell Lung Cancer

LETTER TO THE EDITOR
EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter
Pei Jye Voon, Dana Wai Yi Tsui, Nitzan Rosenfeld, and Tan Min Chin

ABOUT THE COVER
Ribbon representation of a homology model of the c-Met specific Anticalin PRS-110. Anticals are engineered human lipocalins that represent a next generation class of drug molecules. The lipocalins have a structurally conserved β-barrel architecture that forms a cup-shaped ligand binding pocket that can accommodate small and large ligands. The β strands (blue) of the lipocalin form the base of the ligand-binding pocket and the entry of the pocket is comprised of four loops connecting the β strands. Novel, target-specific Anticals are generated by engineering mutations (pink regions, PRS-110 mutations) within these four loops and then selecting variants with the desired binding activity. For details, see article by Olwill and colleagues on page 2459.